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Collectively, the ribosomopathies are caused by defects in ribosome biogenesis. Although these dis-
orders encompass deﬁciencies in a ubiquitous and fundamental process, the clinical manifestations
are extremely variable and typically display tissue speciﬁcity. Research into this paradox has offered
fascinating new insights into the role of the ribosome in the regulation of mRNA translation, cell
cycle control, and signaling pathways involving TP53, MYC and mTOR. Several common features
of ribosomopathies such as small stature, cancer predisposition, and hematological defects, point
to how these diverse diseases may be related at a molecular level.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The ribosomopathies are a diverse group of disorders which,
despite their heterogeneity at a clinical level, affect the same
biochemical process. They are each caused by mutations in a gene
encoding either a ribosomal protein, or a component of the appa-
ratus required for ribosome biosynthesis. Ribosomes are large
and complex molecules comprised of both RNA and protein,
assembled into a functional, multi-subunit enzyme. The large or
60S ribosomal subunit is composed of the 28S, 5S and 5.8S rRNAs,
and 47 proteins; the small or 40S ribosomal subunit is composed of
the 18S rRNA and 33 proteins. Assembly of a functional 80S ribo-
some, containing both the small and large subunits, is a complex,
multi-step process. It requires the coordinated activities of all three
RNA polymerases, 75 small nucleolar RNAs (snoRNAs), and roughly
200 other non-ribosomal factors that are involved in the transcrip-
tion, export, translation, re-importation, modiﬁcation, assembly,
and maturation of the ribosomal subunit components. These
non-ribosomal factors include helicases, exo- and endonucleases,
methyltransferases, and isomerases which modify the nascent
rRNA [1–3]. To generate the mature 18S, 28S, and 5.8S rRNAs, a
precursor 45S rRNA is transcribed by RNA polymerase I as a long
polycistronic transcript which is then extensively processedthrough cleavage and modiﬁcation events, ensuring equimolar
amounts of these rRNA species. The 5S rRNA is transcribed inde-
pendently by RNA polymerase III in the nucleoplasm, undergoing
its own maturation pathway before re-importation into the
nucleolus [4]. The ribosomal protein genes are transcribed by
RNA polymerase II, and assembled with nascent rRNA in the
nucleolus. The pre-60S and pre-40S ribosomal subunits are ex-
ported into the cytoplasm where they undergo ﬁnal maturation
steps to become the mature 60S and 40S subunits, which can then
join to form the 80S ribosome.
Individually, the ribosomopathies are rare and phenotypically
unique. Intuitively, mutations affecting the ribosome, a molecule
essential for protein synthesis in every cell, should affect all tissues
and cell types. On the contrary, ribosome biogenesis disorders are
highly heterogeneous in both their physical manifestations and
modes of inheritance, and there is a surprising tendency toward
tissue speciﬁcity in these diseases (Table 1). Among the autosomal
dominant ribosomopathies are Diamond–Blackfan anemia (OMIM
#105650), primarily characterized by macrocytic anemia [5–9];
Treacher Collins syndrome (OMIM #154500 and #613717), which
also has an autosomal recessive form (OMIM #248390) and is pri-
marily a disorder of craniofacial abnormalities [10–14]; isolated
congenital asplenia (OMIM #271400), a disorder of spleen devel-
opment leading to severe bacterial infections [15]; and the autoso-
mal dominant form of aplasia cutis congenita (OMIM %107600), a
non-syndromic disorder of skin development usually localized to
the scalp [16]. The ribosomopathies inherited in an autosomal
recessive fashion include Shwachman–Diamond syndrome (OMIM
Table 1
The ribosomopathies, including putative mechanisms causing tissue speciﬁcity.
Disease Clinical manifestations Gene Function in ribosome
biogenesis
Occurrence Putative mechanism of
speciﬁcity
References
Autosomal dominant
Diamond–Blackfan anemia Anemia, bone marrow failure, craniofacial
abnormalities, cardiac defects, cancer
predisposition, pre- and postnatal growth
retardation, thumb abnormalities, heart defects
RPS7, RPS10,
RPS17, RPS19
RPS24, RPS26,
RPL5, RPL11,
RPL26, RPL35A
Ribosomal proteins 1 in 100000-1 in
200000 live births
Translation of IRES-containing
BAG1 and CSDE1 mRNAs in
erythroid progenitors
[5–9,38]
Treacher Collins syndrome Craniofacial abnormalities, occasional
microcephaly, mental retardation and
psychomotor delay
TCOF1, POLR1D,
POLR1C
Transcription of rRNA genes 1 in 40000-1 in
70000
Treacle strongly expressed in
neural crest cells; Treacle
interaction with UBF, ﬁbrillarin,
NOP56, Plk1
[10,12–14,39,40]
Isolated congential asplenia Agenesis or hypoplasia of spleen leading to
immunodeﬁciency
RPSA Small subunit ribosomal
protein
73 cases reported Unknown [15,41,42]
Aplasia cutis congenita Agenesis of skin, usually on scalp vertex BMS1 Ribosomal GTPase >500 cases Unknown [16,43,44]
Autosomal recessive
Shwachman–Diamond
syndrome
Exocrine pancreas insufﬁciency, growth
retardation, hematologic defects, skeletal
abnormalities, cancer predisposition
SBDS Removal of eIF6 from 60S in
ﬁnal maturation step,
allowing binding of 40S and
60S subunits
1 in 76000 live
births
SBDS strongly expressed in
developing pancreas
[17,18,45–48]
Bowen–Conradi syndrome Severe pre- and postnatal growth retardation,
psychomotor retardation, microcephaly,
micrognathia, joint contractures, rockerbottom
feet
EMG1 Pseudouridine-N1-speciﬁc
methyltransferase
1 in 355 live births
in Hutterite
population
Unknown [19,49–52]
Cartilage hair hypoplasia Short stature, sparse hair, immunologic defects,
hematological defects, malabsorption, cancer
predisposition
RMRP Pre-rRNA cleavage Amish: 1 in 500-1 in
1000; Finnish: 1 in
23000
Short stature related to rRNA
cleavage defect; cancer
predisposition putatively caused
by defective cyclin B cleavage
[20,21,53,54]
Anauxetic dysplasia Severe short stature, hypodontia, mental
retardation
RMRP Pre-rRNA cleavage 7 cases reported Short stature related to rRNA
cleavage defect; cyclin B
cleavage unaffected thus no
cancer predisposition
[20,21,53,54]
Alopecia, neurological defects
and endocrinopathy
syndrome
Hypoplastic hair, microcephaly, mental
retardation, progressive motor retardation,
adrenal insufﬁciency
RBM28 Nucleolar component of the
spliceosomal small nucleolar
ribonucleoprotein, necessary
for 60S biogenesis
5 cases reported Unknown [23,55,56]
North American Indian
childhood cirrhosis
Transient neonatal jaundice progressing to
biliary cirrhosis
CIRH1A Pre-rRNA processing Carrier status: 1 in
10 in Quebec
Ojibway-Cree
population
Cirhin strongly expressed in
developing liver
[24,25,57–59]
X-linked recessive
X-linked dyskeratosis congenita
and Hoyeraal–Hreidarsson
syndrome
Abnormal skin pigmentation, nail dystrophy,
leukoplakia, bone marrow failure, cancer
predisposition, short stature, microcephaly,
immunodeﬁciency
DKC1 Pseudouridine synthase 1 in 1000 000 Translation of IRES-containing
mRNAs including p27, XIAP, Bcl-
xL
[26,28,60–62]
Sporadic
5q syndrome Macrocytic anemia, predisposition to acute
myeloid leukemia
RPS14 Small subunit ribosomal
protein
Unknown Unknown [31]
T cell acute lymphoblastic
leukemia
Leukemia affecting the T-cell lineage RPL5, RPL10, RPL22 Large subunit ribosomal
proteins
In T-ALL: RPL5
mutations 5.2%,
RPL10 mutations
1.9%, RPL22
deletions 10%
RPL22 deﬁciency blocks ab T
cell development, unknown
[32,33,63]
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ciency [17,18]; Bowen–Conradi syndrome (#211180), character-
ized by severe growth and psychomotor delay, and death in early
childhood [19]; cartilage hair hypoplasia (OMIM #250250), a dis-
order of short stature and hypoplastic hair [20,21], and its variants
anauxetic dysplasia (OMIM #607095) [21] and metaphyseal dys-
plasia without hypotrichosis (OMIM #250460) [22]; alopecia, neu-
rological defects, and endocrinopathy syndrome (OMIM #612079),
causing hair loss, microcephaly, mental retardation, and adrenal
insufﬁciency [23]; and North American Indian childhood cirrhosis
(OMIM #604901), which results in biliary cirrhosis [24,25]. Dys-
keratosis congenita, characterized by abnormal skin pigmentation,
nail dystrophy, and leukoplakia, has an X-linked form (OMIM
#305000, including the severe form known as Hoyeraal–Hreidars-
son syndrome), autosomal dominant (OMIM #127550, #613989,
#613990) and autosomal recessive forms (OMIM #224230,
#613988), although the best evidence for a ribosome biogenesis
defect is found in the X-linked form [26–30]. Many ribosomopa-
thies are accompanied by a predisposition to cancer, and evidence
that ribosomal defects can drive malignant transformation is
mounting; 5q syndrome, a form of macrocytic anemia with pre-
disposition to cancer, is caused by haploinsufﬁciency of RPS14
due to the sporadic deletion of part of the long arm of chromosome
5 [31]. Somatic mutations in RPL5, RPL10, and RPL22 have been
associated with T-cell acute lymphoblastic leukemia [32,33]. De-
spite the phenotypic heterogeneity, several characteristics, includ-
ing small stature, microcephaly, hematological defects, and
predisposition to cancer [34–36] are shared among many of the
disorders. Immune defects have also been proposed to be a hall-
mark of ribosomopathies [37].
Although the speciﬁc mechanism underlying the ribosomopa-
thies is frequently unclear, the generally accepted etiology is that
processing delays or defects in rRNA maturation, resulting in an
imbalance of mature ribosomes, lead to reduced rates of protein
synthesis and cell proliferation. However, it has become clear that
the speciﬁcity and activity of the ribosome is regulated, and
changes to its composition may begin to explain the heterogeneity
among ribosomopathies. Examples of ribosome diversity in
numerous organisms are increasingly common, and will not be
covered in full here as the topic has been extensively reviewed
elsewhere (see [64–66]). Instead, we will focus on vertebrate ribo-
some heterogeneity and its relevance to human disease. Herein, we
review several different mechanisms which have been proposed to
underlie the tissue speciﬁcity of ribosome biogenesis disorders,
including the selective translation of speciﬁc mRNAs directed by
the ribosome, extra-ribosomal functions of ribosomal proteins
and ribosomal biogenesis factors, and differential requirements
for ribosomes in different tissues. In addition, the diverse roles
played by regulatory pathways in modulating ribosome biogenesis
disorders will be discussed.
2. Mechanisms underlying tissue speciﬁcity in ribosomopathies
2.1. Selective translation of internal ribosome entry site mRNAs: X-
linked dyskeratosis congenita and Diamond–Blackfan anemia
Several studies have shown that the cellular environment can
cause the ribosome to display a preference for translating speciﬁc
types of mRNAs. The discovery that ribosomes can preferentially
translate certain mRNAs was ﬁrst described in the context of viral
infection, when cap-dependent translation is repressed in favor of
the translation of viral mRNAs [67,68]. These viral mRNAs contain
internal ribosomal entry sites (IRESs) in their 50-untranslated re-
gion (UTR) which allow ribosome binding even in the absence of
a cap. IRES-directed translation has since been found in numerouscellular mRNAs, often in response to stress [69,70]. For example,
cap-dependent translation is repressed during apoptosis, hypoxia,
and mitosis, allowing translation of IRES-containing mRNAs which
include TP53, X-linked inhibitor of apoptosis (XIAP), MYC, and
certain cyclin-dependent kinases [70,71]. When cap-dependent
translation is down-regulated during mitosis, roughly 3% of
mRNAs, many of which contain IRESs, remain associated with pol-
ysomes [72]. However, there are likely other levels of control over
IRES-containing mRNAs, as translation from only a subset of IRES
elements occurs under a given condition. For example, of the
IRES-containing mRNAs, one isoform of cyclin-dependent kinase
11, CDKp58, is translated during mitosis, however c-MYC is not.
On the other hand, c-MYC mRNA is translated during apoptosis,
while the IRES-containing nucleophosmin mRNA is not [70,73].
This second layer of speciﬁcity may be mediated by binding of
cell-cycle or tissue-related factors to speciﬁc mRNAs, or it could
be due to alterations in the ribosome itself, which change its ability
to recognize and bind different IRES elements under different
conditions.
X-linked dyskeratosis congenita is caused by mutations in
DKC1, encoding dyskerin, a component of an H/ACA box small
nucleolar ribonuclear particle (snoRNP) responsible for isomerisa-
tion of uridine to pseudouridine [26,60,74]. Dyskerin is also a part
of the telomerase complex, and defects in both ribosome biogene-
sis and telomere maintenance have been shown in patient cells
and in mouse models of the disease [26–28,75,76]. Alterations in
rRNA pseudouridylation have been shown to be deleterious for
ribosome biogenesis and function in numerous organisms, most
likely by altering the afﬁnity of the ribosome for mRNAs [77,78].
Mutations causing X-linked dyskeratosis congenita result in a
speciﬁc reduction of IRES-mediated mRNA translation in patient
lymphoblasts and ﬁbroblasts, without affecting global levels of
protein synthesis [61]. In particular, translation of the tumor
suppressor p27, and the anti-apoptotic proteins XIAP and Bcl-xL,
is signiﬁcantly reduced. The cells are also deﬁcient in translation
of exogenous viral IRES-containing mRNAs, suggesting a global
reduction of IRES element translation due to the loss of rRNA
pseudouridylation.
IRES-directed translation can affect the organism at multiple
levels; in dyskeratosis congenita, apoptosis, tumor suppression,
and cell cycle progression are all misregulated. The misregulation
of apoptosis, reﬂected by increased apoptosis in hematopoietic
progenitors and stem cells, results in a bone marrow defect. The in-
creased cancer susceptibility seen in X-linked dyskeratosis congen-
ita patients [61] is likely secondary to the IRES-mediated reduction
in p27 levels. Additionally, disruption of dyskerin leads to accumu-
lation of cells in the G2/M phase of the cell cycle, resulting in re-
duced proliferation rates [79,80], which may be attributed to
failure to complete IRES-directed translation following down-regu-
lation of cap-dependent translation at the beginning of mitosis.
The translation of CDKp58 is directed by an IRES element, and the
resulting protein is necessary for progression through M phase
[81]. These ﬁndings demonstrate not only that rRNA modiﬁcation
is crucial for ribosome speciﬁcity, but also that defective rRNA
modiﬁcation can lead to disruption of IRES-based translation. Gi-
ven that IRES-containing mRNAs are expressed under particular
conditions, it seems likely that these defects would only be present
at speciﬁc times or in speciﬁc tissues.
Diamond–Blackfan anemia (DBA) is characterized by macro-
cytic anemia with reduced numbers of erythroid progenitors in
the bone marrow. It is caused by mutations in genes encoding
components of either the small or large ribosomal subunits, includ-
ing RPS19, RPS7, RPS10, RPS17, RPS24, RPS26, RPL5, RPL11, RPL35A,
and RPL26. As RPS19 mutations account for 25% of DBA cases
[5,9,82], this gene has been the most extensively studied.
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ative capacity by stalling the cell cycle at G0, in addition to impair-
ing erythroid differentiation, but without signiﬁcantly affecting
myeloid differentiation [83,84]. In mice, mutations in Rps19 and
Rpl11 result in deﬁcient IRES-mediated translation of BCL2-associ-
ated anathogene 1 (Bag1) and cold shock containing domain E1
(Csde1) in erythroblasts. Reduced translation of BAG1 and CSDE1,
due to an alteration in ribosome speciﬁcity for IRES-containing
mRNAs, is also detected in DBA patient cells [38]. Because these
proteins are necessary for erythroid generation, their deﬁciency re-
sults in an erythroid progenitor defect in DBA patient cells. Further
evidence comes from studies in mice where the normal expression
levels of Bag1 and Csde1 are low in myeloid progenitor cells but
high in erythroid progenitors. A Bag1 knockout shows a reduction
in erythroid progenitors, and shRNA knockdown of Csde1 in ery-
throblasts inhibits their proliferation and maturation [38]. This
suggests that ribosomal proteins play a role in the recognition of
speciﬁc mRNAs for translation, although it is not clear if this is
the case for mutations in ribosomal protein-encoding genes other
than RPS19 and RPL11. Notably, knockdown of RPS19 and RPL11
both negatively affect translation of a control IRES mRNA as well,
indicating that cap-independent translation as a whole may be
deﬁcient [38]. Further investigation is necessary to determine
whether IRES-dependent mRNAs aside from BAG1 and CSDE1 are
relevant to the DBA phenotype.
Although macrocytic anemia is consistently detected in DBA pa-
tients, other phenotypes are variable and establishing genotype-
phenotype correlations has been difﬁcult [85,86]. Despite this, a
few correlations have been made. For example, RPL5 mutations
are correlated with craniofacial malformations including cleft pal-
ate, and RPL11mutations are associated with thumb abnormalities
[86]. This suggests that the mechanism leading to macrocytic ane-
mia is common to these deﬁciencies, but that each ribosomal pro-
tein may also have unique roles in mediating the other phenotypes
of DBA, whether through their function within the ribosome, or via
extra-ribosomal functions.
2.2. Extra-ribosomal functions and binding partners: Treacher Collins
syndrome and cartilage hair hypoplasia/anauxetic dysplasia
Numerous ribosomal proteins seem to have functions outside
their role in the ribosome, the best-studied of which is mediation
of the cell cycle (see TP53 section below). Extra-ribosomal func-
tions of ribosome biogenesis factors are also common. Perturbation
of these functions may contribute to the phenotype in ribosome
biogenesis disorders, mediated at least in part by their interacting
partners. Treacher Collins syndrome (TCS) is a disorder of craniofa-
cial development caused by mutations in TCOF1 (encoding the pro-
tein Treacle), POLR1C, or POLR1D (encoding subunits of RNA
polymerase I and RNA polymerase III respectively) [14]. Autosomal
dominant TCS caused by mutations in TCOF1 accounts for the
majority of cases [87,88]. There is a clear temporal aspect to the
disease, as Tcof1 expression in the mouse embryo is strong in
embryonic development, particularly in the developing branchial
arches, and diminishes to near background levels by embryonic
day 10.0 [10]. Mouse and zebraﬁsh models of the disease have re-
vealed a deﬁciency speciﬁcally in migrating neural crest cells due
to reduced proliferation rates and increased apoptosis [13,89]. This
defect in neural crest cells is proposed to underlie the hearing loss
in Treacher Collins syndrome, as the affected middle ear is neural-
crest derived, while the unaffected inner ear does not originate
from neural crest cells [90]. Although the exact function of Treacle
is unknown, the phenotype of Treacher Collins syndrome appears
to be directly mediated by binding of Treacle to other factors. For
instance, Treacle interacts with upstream binding factor (UBF),
which modulates RNA polymerase I activity, and a reduction inTreacle levels inhibits transcription of the rRNA genes [12]. In
Xenopus oocytes, Treacle was shown to interact with ﬁbrillarin,
an RNA and DNA methyltransferase [91,92], and NOP56, a compo-
nent of an RNP methyltransferase complex [93]. TCOF1 knockdown
therefore causes a reduction in 20-OH methylation in nascent rRNA
[39]. Reduction of rRNA transcription and modiﬁcation due to
Treacle haploinsufﬁciency is thus proposed to underlie the prolif-
eration defect in neural crest cells, which in turn leads to hypopla-
sia of the facial bones [12,39].
In addition to craniofacial abnormalities, Treacher Collins syn-
drome patients may present with microcephaly and psychomotor
retardation, indicating a neurological defect. A mouse model of
Treacher Collins syndrome displaying reduced brain size has re-
vealed that Treacle also has an important role outside of ribosome
biogenesis. This appears to be mediated by an interaction with
Polo-like kinase 1 (Plk1), which is necessary for mitotic progression
via its role in spindle orientation [40]. A reduction in the Treacle-
Plk1 interaction is thought to underlie a reduction in neural pro-
genitors during cortical neurogenesis, due to improper mitotic
spindle formation. This suggests that the neurological phenotype
in Treacher Collins syndrome is mediated by extra-ribosomal
functions of Treacle, in addition to its role in ribosome biogenesis,
which is linked to the craniofacial phenotype. Interestingly, mitotic
spindle localization has been shown for other ribosomopathy-
associated proteins. SBDS, the Shwachman–Diamond syndrome
protein, binds to the mitotic spindle in bone marrow cells, lympho-
blasts, and skin ﬁbroblasts, and knockdown by siRNA increases the
number of atypical mitoses in human ﬁbroblasts [94]. Knocking
down dyskerin also leads to multi-polar mitotic spindle defects
in HeLa cells, possibly through the association of dyskerin with
CDKp58 [79,81,95]. Additionally, dyskerin-depleted U2OS cells (a
telomerase-negative osteosarcoma cell line) [79], and mouse
embryonic ﬁbroblasts [80] arrest in G2/M phase, although this is
not the case in the telomerase-positive UM-SCC1 oral squamous
cell carcinoma or HeLa cell lines [79]. The yeast homolog of
EMG1, the protein associated with Bowen–Conradi syndrome,
shows spindle localization [96], and lymphoblasts from Bowen–
Conradi syndrome patients accumulate in G2/M phase, indicating
a possible defect in mitotic progression (Armistead et al., unpub-
lished data). In HeLa cells stably expressing either His-tagged or
EGFP-tagged Cirhin, the protein associated with North American
Indian childhood cirrhosis, Cirhin is localized to the chromosome
periphery throughout mitosis. Similar localization was shown for
HepG2 cells, a hepatocyte-like cell line [97]. Mitotic spindle associ-
ation may be a common extra-ribosomal function of many proteins
associated with ribosome biogenesis disorders, and future work
will show if this is a contributing factor in cell proliferation defects
and cancer progression.
Cartilage hair hypoplasia (CHH) is a form of short-limbed
dwarﬁsm, accompanied by sparse hair, immunologic and hemato-
logical defects, and increased instances of malignancy [20,22]. The
related disease, anauxetic dysplasia (AD), is characterized by a
more severe skeletal phenotype of extreme short stature, but AD
patients do not display increased cancer susceptibility [21]. Both
diseases are caused by mutations in RMRP, the RNA component
of the mitochondrial RNA-processing endoribonuclease RNase
MRP, an enzyme with numerous substrates in the nucleolus and
in mitochondria, including rRNA and mRNA [54]. The short stature
in CHH and AD has been attributed to failure of 5.8S rRNA cleavage
during maturation, leading to reduced proliferation speciﬁcally in
chondrocytes [21,53]. On the other hand, susceptibility to cancer
in CHH has been attributed to the impairment of cyclin B mRNA
degradation by RNase MRP, which alters the spindle assembly
checkpoint during mitosis [21]. Patients with AD do not accumu-
late cyclin B mRNA and are not predisposed to malignancy [21].
Thus, in a rare clear-cut example, the phenotypic differences
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of RNase MRP, as CHH patients display defects in both rRNA and
mRNA cleavage, while AD patients are only deﬁcient in rRNA
cleavage.
A less understood, though well-studied, example is dyskeratosis
congenita; the contribution of defects in ribosome biogenesis ver-
sus defects in telomerase function to the phenotype are difﬁcult to
unravel [26–28,75,76]. Ribosome biogenesis defects in mouse
models of the disease, causing a proliferative defect not associated
with short telomeres, would seem to point to a purely ribosome-
related disease [29]. Other studies in cell lines from dyskeratosis
congenita patients indicate that the reduced proliferation rates
are unrelated to ribosome biogenesis defects [27]. It may not be
possible to resolve this apparent paradox using mouse models of
the disease, since the much longer telomeres in mice mean that
they do not completely recapitulate the human condition [98].
2.3. Differential requirement for ribosome biogenesis factors: North
American Indian childhood cirrhosis, Shwachman–Diamond
syndrome, and Tail short mouse
Although the ribosomal genes are generally considered to be
‘‘housekeeping’’ genes due to their ubiquity, it is becoming under-
stood that at least some of the ribosomal protein genes display
temporal and spatial variation, despite a general tendency toward
coordinate regulation [99–102]. A screen of 72 ribosomal proteins
in 14 tissue and cell types of the mouse embryo showed heteroge-
neous and non-overlapping patterns of expression [103]. A recent
study in mouse suggests that the most recently evolved ribosomal
protein paralogs are more likely to display tissue-speciﬁc variation,
indicating an evolutionary need for ribosome variation [104]. If the
ribosomal proteins have variable expression, it seems likely that
variation in ribosome biogenesis factor distribution among tissues
and throughout development also contribute to ribosomopathy
phenotypes.
North American Indian childhood cirrhosis (NAIC) is caused by a
mutation in CIRH1A, encoding the protein Cirhin [58]. NAIC
presents in childhood as transient jaundice, progresses to biliary
cirrhosis and portal hypertension, and liver transplantation is cur-
rently the only treatment. Among the ribosomopathies, NAIC has
the distinction of affecting a single organ, making analysis of the
defect more straightforward. The yeast homolog of Cirhin, Utp4,
is a member of the small ribosomal subunit processome and is
essential for ribosomal RNA maturation [24,25]. During mouse
embryonic development, Cirhin is highly expressed in the liver at
embryonic day 11.5, with much lower levels of expression in the
somites, brain, and craniofacial structures [58]. Zebraﬁsh show
similar results, with widespread expression of cirh1a at 20 h post
fertilization, peak expression at 3 days post fertilization restricted
to the liver, gallbladder, pancreas, and anterior intestine, and much
lower levels in the brain and eye [59]. When cirh1a was knocked
down by morpholino injection, morphants showed tp53-depen-
dent defects in development of the biliary system, with no defects
observed in other tissues [59]. In this case, it seems that the high
requirement for Cirhin in the liver makes it most sensitive to a loss
of Cirhin function.
Shwachman–Diamond syndrome (SDS) is a disorder of exocrine
pancreas insufﬁciency, bone marrow dysfunction and increased
cancer risk. In SDS, mutations in the SBDS gene result in deﬁcien-
cies in the 60S ribosomal subunit because of a failure in the re-
moval of eukaryotic translation initiation factor 6 (eIF6) from the
ribosome in a ﬁnal maturation step [47,105]. SDS patients suffer
from exocrine pancreatic insufﬁciency, and it has never been clear
whether the symptoms result from reduced protein synthesis rates
in the pancreas that lead to insufﬁcient levels of pancreatic en-
zymes, or whether the pancreas simply does not develop properly.An examination of sbds expression in zebraﬁsh throughout devel-
opment showed that sbds in the developing pancreas persists over
time, while it diminishes in other tissues including the adjacent gut
and liver [45]. Knockdown of sbds in zebraﬁsh results in reduced
expansion speciﬁcally in exocrine pancreatic cells without affect-
ing cell proliferation in other tissues [45,48]. Notably, the pancreas
defect precedes the production of pancreatic enzymes, indicating a
developmental problem rather than a simple protein synthesis
deﬁciency resulting in insufﬁcient enzymes [48]. Together, these
zebraﬁsh models of SDS suggest that the strong pancreatic pheno-
type correlates with the high and continuing levels of sbds expres-
sion, and that visceral organs with lower expression such as gut
and liver are affected to a lesser extent. It becomes more difﬁcult
to unravel the phenotype when it is considered that SDS patients
also display hematological defects, even though bone marrow
has relatively low levels of SBDS expression in humans [17].
Differential expression of the ribosomal protein Rpl38 has also
been shown to play a role in mediating the phenotype in mice deﬁ-
cient in ribosome biogenesis. This is demonstrated in the sponta-
neous dominant mouse mutant, Tail short, which is characterized
by a short and kinky tail, homeotic transformations of the skeleton,
facial malformations, and eye abnormalities. Mutations in the large
ribosomal subunit protein gene Rpl38 result in the reduction of
translation of a subset of Homeobox (Hox) mRNAs. Global protein
synthesis is unchanged, and the speciﬁc translation of the Hox
mRNAs is unrelated to IRES elements [103]. Similar to the zebraﬁsh
models of NAIC and SDS, Rpl38 expression varies among tissues,
and in general, the highest expression is found in the most severely
affected tissues. In particular, Rpl38 expression is enriched in the
somites along the entire anterior-posterior axis during somitogen-
esis, pointing to a role in axial vertebral patterning. The Hox trans-
lation defect was detected in the embryo at approximately
embryonic day 11, long before the morphological defects become
evident. This suggests that the speciﬁc translational control of a
subset of mRNAs, mediated by Rpl38 itself, underlies the develop-
ment of the patterning defects. The tissue-speciﬁc effect reﬂects
the fact that the tissues most sensitive to Rpl38 perturbation are
those expressing the highest levels of the protein [103].
Thus, differential expression of ribosome biogenesis factors and
ribosomal proteins can affect the phenotype of a disease. It should
be noted however, that this hypothesis cannot completely explain
the tissue speciﬁcity. For example, high Rpl38 expression was also
found in the mouse kidney, an organ which is unaffected in the
Rpl38 mutant. This, combined with the bone marrow dysfunction
seen in Shwachman–Diamond syndrome despite low levels of SBDS
expression in that tissue, suggests that expression levels do not
always predict demand.3. The diverse roles of regulatory pathways in ribosome
biogenesis
3.1. Tp53
The TP53 tumor suppressor pathway stands as a strong check-
point to verify that ribosome biogenesis is intact before allowing
cell division. In a healthy cell, the E3 ubiquitin ligase MDM2 binds
and ubiquitinates TP53, thereby targeting it for degradation by the
proteasome and maintaining it at low levels. In a cell where ribo-
some biogenesis has been perturbed, the balance between rRNA
and ribosomal protein synthesis becomes uncoupled, leading to
free ribosomal proteins that cannot be incorporated into a func-
tional ribosome [106–110]. In another example of an extra-ribo-
somal function for ribosomal factors, certain free ribosomal
proteins including RPL5 [111], RPL11 [112], RPL23 [113,114],
RPL26 [115], RPS3 [116] and RPS7 [117] bind and segregate
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and/or apoptosis ensue, ensuring that cells with deﬁciencies in
ribosome biogenesis do not survive [107,109,118–121]. Perturba-
tion of ribosomal proteins can thus lead to the activation of a
TP53-mediated nucleolar stress response [119,121], although the
TP53 response can vary depending on the ribosomal protein in-
volved [122], and TP53 stabilization has been observed even in
the absence of nucleolar disruption [120].
The link between the TP53 pathway and ribosome biogenesis
has been exploited in animal models of ribosome biogenesis as a
treatment for the disorder. Remarkably, in a mouse model of Trea-
cher Collins syndrome, loss of one Trp53 allele completely rescues
the phenotype by decreasing apoptosis in neuroepithelial and neu-
ral crest cells [123]. Other examples of ribosome insufﬁciency,
including mutations in Rps20 [124], Rpl24 [125], Rps7 [126], and
the 5q syndrome-associated protein Rps14 [127], can all be res-
cued in mice by the ablation of the Trp53 pathway. However, the
contribution of TP53 to the regulation of ribosome biogenesis is
far from clear, as recent studies have shown variable responses
to Trp53 inhibition or knockout. In Rpl38, Rps19, and Rpl11 mutant
mice, as well as an Emg1 knockout mouse, the phenotype is refrac-
tory to Trp53 inhibition [38,103,128]. Interestingly, ablation of the
TP53 checkpoint in sbds knockdown zebraﬁsh ameliorates the skel-
etal phenotype and improves the overall health of the embryos
[48]. However, the pancreatic organogenesis defect is not rescued,
suggesting that the phenotype is only partially mediated by the
TP53 pathway. Similarly, TP53 knock down in a zebraﬁsh model
of Diamond–Blackfan anemia rescued the morphological abnor-
malities, but did not alter the erythropoietic defect [129,130].
The selective contribution of the TP53 checkpoint to individual
ribosomopathies likely plays a role in the variable phenotypes in
ribosome biogenesis disorders, including cancer progression, and
is just beginning to be appreciated. Other pathways may mediate
the phenotype in the absence of TP53 involvement; for example,
p21 is sometimes up-regulated in ribosome biogenesis disorders
even in the absence of TP53 stabilization [16,131]. Another TP53-
independent mechanism involves dysregulation of retinoblastoma
phosphorylation. When ribosome biogenesis is impaired, for exam-
ple by depletion of ribosome biogenesis factor pescadillo [132], the
cyclin-dependent kinase inhibitor p27 is up-regulated, leading to
reduced phosphorylation of the retinoblastoma protein. In the ab-
sence of phosphorylation, the retinoblastoma protein remains
bound to transcription factor E2F1, preventing translation of genes
necessary for S-phase progression [133].
3.2. mTOR
Ribosome biogenesis and cellular environment are linked by the
mammalian target of rapamycin (mTOR) pathway, which senses
nutrient availability, hormones, energy levels and cellular stress.
In situations where increased ribosome biogenesis is required,
mTOR complex 1 promotes rDNA transcription by positively regu-
lating RNA polymerase I, and plays a role in the processing of pre-
rRNA to its mature forms [134]. In addition, it phosphorylates
S6K1, which in turn phosphorylates small ribosomal subunit pro-
tein RPS6. The phosphorylated RPS6 appears to alter the speciﬁcity
of the ribosome, conferring it with a preference for translating 50
terminal oligopyrimidine (50-TOP) mRNAs, a group of mRNAs
which includes ribosomal protein genes [135–137]. Thus, the
activity of mTOR, modulated by the local environment in a given
tissue, can directly regulate ribosome biogenesis. In an example
relevant to Diamond–Blackfan anemia, mTOR is activated in re-
sponse to erythropoietin, resulting in increased formation of the
ribosome scanning complex speciﬁcally in erythroblasts [38,138].
Differential effects of ribosome biogenesis deﬁciency on mTOR sig-
naling have also been shown in the brain. When rRNA transcriptionis inhibited, mTOR signaling, as measured by RPS6 phosphoryla-
tion, in increased in hippocampal neurons [139], but inhibited in
dopaminergic neurons [140]. However, unlike TP53 stabilization,
mTOR pathway activity is rarely investigated in ribosome biogen-
esis disorders, making it difﬁcult to assess its role in ribosomopa-
thy phenotypes.
3.3. Myc
Another master coordinator of cell growth and division, the
oncogenic transcription factor MYC, has been shown to directly
bind and stimulate the transcription of the rRNA genes [141].
MYC recruits the selectivity factor 1 (SL1) complex and inﬂuences
transcription by RNA polymerase I via stabilization of the SL1-UBF
complex. Thus deregulation of MYC activity can increase ribosome
production, and drive uncontrolled cell proliferation. One example
is the myelodysplastic 5q syndrome. In a healthy cell, the small
ribosomal subunit protein RPS14 binds c-MYC and inhibits its
activity, reducing cell proliferation [142]. In 5q syndrome,
RPS14 is haploinsufﬁcient [31], removing one layer of MYC regula-
tion and promoting uncontrolled cell growth. It appears that in
some cases ribosome biogenesis and MYC are interdependent, as
haploinsufﬁciency for ribosomal protein genes, which reduces
ribosome levels to normal in cancerous cells, is able to suppress
the oncogenic activity of MYC [143]. While this is difﬁcult to recon-
cile with the increased incidence of cancer in ribosomopathy pa-
tients, who are haploinsufﬁcient for ribosomal proteins, the
disruption of ribosome biogenesis may dysregulate MYC function,
and eventually lead to cancer. Which cell types and tissues are af-
fected is likely dictated by many of the factors described above.
Notably, MYC translation is mediated by an IRES, and mutations
in ribosomal proteins or ribosome biogenesis factors which alter
the speciﬁcity of the ribosome could disrupt the balance of MYC
synthesis.
The TP53, mTOR, and MYC pathways are evidently each impor-
tant for ribosome biogenesis, although their individual contribu-
tions to tissue-speciﬁc effects in ribosomopathies are currently
unclear. It has become apparent, however, that these pathways
interact and inﬂuence each other. It has been shown that in
MYC-dependent cancers, tumor initiation and maintenance re-
quires the phosphorylation of eukaryotic translation initiation fac-
tor 4E-binding protein 1 (4EBP1) by mTOR [144]. Phosphorylation
of 4EBP1 prevents it from negatively regulating the translation ini-
tiation factor eIF4E, which binds the 50 cap on mRNA and recruits
the 40S ribosomal subunit, driving the increased protein synthesis
necessary in cancer cells. Thus, blocking mTOR-dependent 4EBP1
phosphorylation may be a therapeutic target in cancers driven by
MYC. The TP53 pathway and MYC are both directly inﬂuenced by
the Diamond–Blackfan anemia-associated ribosomal protein
RPL11. Free RPL11 stabilizes TP53 by binding and sequestering
MDM2 (see above), and can also bind the N-terminus of MYC
[145]. MYC induces RPL11 transcription, and RPL11 overexpression
represses MYC transactivation in a negative feedback loop
[145,146]. Thus, RPL11 can act through both TP53 and MYC to ar-
rest the cell cycle during situations of aberrant ribosome biogene-
sis. Given the layers of interaction in ribosomal biogenesis
regulatory pathways, it remains a major challenge to deﬁne their
discrete roles in mediating particular ribosomopathy phenotypes.4. Conclusions
The tissue-speciﬁc effects commonly displayed in the ribosom-
opathies can clearly be caused by multiple factors. These include
alteration of ribosome speciﬁcity due to changes in rRNA modiﬁca-
tion or changes in ribosomal protein content, differential
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alterations in binding with partners of the affected protein, and dif-
ferential response to regulatory signaling pathways such as TP53.
The contributions of these factors to ribosome biogenesis disorders
are not mutually exclusive, and the etiologies of ribosomopathies
are likely highly complex. The role of these factors in the pheno-
type of a ribosomopathy must be evaluated before an effective
treatment can be developed, and careful analysis is needed in stud-
ies of each ribosomopathy to tease out which factors hold the most
promise as targets for treatment.
Innovative use of existing techniques has already proven
successful in investigating spatial and temporal differences in ribo-
some function. Dicistronic reporter transcripts have been used pre-
viously to measure levels of cap-dependent versus IRES-dependent
translation [61,147]. Bellodi et al. generated a translation reporter
mouse using a similar system, which systemically expresses a
Renilla luciferase reporter driven by cap-dependent translation,
and a ﬁreﬂy luciferase reporter driven by the hepatitis C virus
(HCV) IRES element. This mouse was employed to determine if
IRES-dependent translation was altered in a model of X-linked dys-
keratosis congenita [148] and in an Rpl38 mutant mouse [103].
This tool could be used to further characterize changes in cap-
dependent versus IRES-dependent translation in multiple different
tissues, and at different stages of development, in health and dis-
ease. Other cis-regulatory elements contained within the mRNA
50 untranslated region, such as upstream open reading frames
and 50-TOPs, can also mediate translation, and may also play a role
in the phenotype of ribosome biogenesis disorders [65,70,136,137].
It is easy to envision how modiﬁed versions of the HCV IRES
reporter mouse could explore how other cis-regulatory elements
drive translation in vivo, by replacing the IRES reporter with the
cis-element of interest. Equally, they could be used to test ribo-
some ﬁdelity in mouse models of ribosomopathies by measuring
frameshifting and stop codon readthrough [147,149]. Kondrashov
et al. have also optimized microscale polysome analysis, isolating
translationally active ribosomes from minute tissue samples dur-
ing mouse development, followed by quantitative PCR in order to
identify preferentially-translated mRNAs [103]. Ribosome proﬁling
techniques involving deep sequencing of ribosome-protected
mRNAs, offer an unbiased approach to identifying the population
of mRNAs translated in a given tissue at a given time [150].
As new ribosome biogenesis disorders are identiﬁed and new
tools become available to unravel their molecular causes, it may
become easier to resolve the ribosomopathy paradox. Overall, it
is increasingly clear that the ribosomopathies are not simply due
to reduced protein synthesis, and are revealing the complex inter-
relationships between ribosome biogenesis and its regulatory
pathways, the cell cycle, and development of multiple tissues.
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